BNTX vs. CRL: BioNTech vs. Charles River Laboratories Stock Comparison

Company Profile

BioNTech (BNTX) and Charles River Laboratories (CRL) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while CRL is classified in Life Sciences Tools & Services.

Charles River Laboratories (CRL) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Charles River Laboratories (CRL) reports 1.27%, ranking against industry peers normally.

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Charles River Laboratories (CRL) reports 1.01%, ranking against industry peers normally.

Both BioNTech (BNTX) at 30.28% and Charles River Laboratories (CRL) at 23.42% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

BioNTech (BNTX) at 4.32% is around its peer norm for revenue growth, while Charles River Laboratories (CRL) at -0.85% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Charles River Laboratories (CRL) reports EPS growth of -1,555.00%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Charles River Laboratories (CRL) at 1.41 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for CRL.

BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Charles River Laboratories (CRL) at 0.87 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Neither BioNTech (BNTX) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BioNTech (BNTX) nor Charles River Laboratories (CRL) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Charles River Laboratories (CRL) trades at 366.87 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

On P/S ratio, both BioNTech (BNTX) at 8.96 and Charles River Laboratories (CRL) at 4.07 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Charles River Laboratories (CRL) at 5.01 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics